XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.21.1

Business concentrations | 3 Months Ended
--- | ---
Mar. 31, 2021
Risks and Uncertainties [Abstract] |
Business concentrations |
16. | Business concentrations
We sell our products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Customers with product revenue equal to or greater than 10% of our total revenue for the periods indicated were as follows:
|  | Three Months Ended March 31,
|  | 2021 |  | 2020
Customer A |  | 13% |  | 26%
Customer B |  | 18% |  | 18%
Customer C |  | 22% |  | 15%
Customer D |  | * |  | 10%
* | Less than 10% of total product revenue
Customers that accounted for 10% or greater of our accounts receivable as of the periods indicated were as follows:
|  | March 31, 2021 |  | December 31, 2020
Customer A |  | 14% |  | 17%
Customer B |  | 20% |  | 19%
Customer C |  | 33% |  | 25%
Customer D |  | * |  | 11%
* | Balance was less than 10% of total accounts receivable
We rely on third parties for the manufacture and supply of our products, as well as third-party logistics providers. In instances where these parties fail to perform their obligations, we may be unable to find alternatives suppliers or satisfactorily deliver our products to our customers on time, if at all. Vendors with product purchases equal to or greater than 10% of our total purchases for the periods indicated were as follows:
|  | Three Months Ended March 31,
|  | 2021 |  | 2020
Catalent |  | 29% |  | 24%
Vendor A |  | 33% |  | 28%
Vendor B |  | 32% |  | 32%
Vendor C |  | * |  | 13%
* | Less than 10% of total product purchases
Vendors that accounted for 10% or greater of our accounts payable as of the periods indicated were as follows:
|  | March 31, 2021 |  | December 31, 2020
Vendor D |  | 19% |  | *
Vendor E |  | * |  | 17%
Vendor F |  | * |  | 16%
Vendor G |  | * |  | 10%
* | Balance was less than 10% of total accounts payable

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration